Pharmacy Policies
Navigate directly to a letter:
-
5
Back to top -
A
- Adakveo.pdf
- Adzynma.pdf
- Agents_to_Treat_Gauchers_Disease.pdf
- Alpha_1_Proteinase_Inhibitors.pdf
- Amtagvi.pdf
- Amyotrophic_lateral_sclerosis_(ALS_agents).pdf
- Anti-CD19_CAR-T_Immunotherapies.pdf
- Anti-FGF23_Monoclonal_Antibodies.pdf
- Antisense_Oligonucleotides_for_DMD.pdf
-
B
Back to top -
C
Back to top -
D
Back to top -
E
Back to top -
F
Back to top -
G
Back to top -
H
- HCP_DMT_for_MS.pdf
- HIF-PH_Inhibitors.pdf
- Hyaluronic_Acid_Derivatives.pdf
- Hydroxyprogesterone_(generic_Delalutin).pdf
-
I
- Immune_Globulins.pdf
- Immunomodulator_Agents_Systemic_Inflammatory_Disease.pdf
- Injectable_Bone_Modifying_Oncology.pdf
- Insulin-Like_Growth_Factor-1_Receptor_(Igf-1r)_Antagonists_For_Thyroid_Eye_Disease.pdf
- Insulin_Pumps-Clean.pdf
-
K
Back to top -
L
Back to top -
M
- Medication_without_specific_criteria.pdf
- Mucopolysaccharidosis_II_(Hunter_Syndrome)_Agents.pdf
- Mucopolysaccharidosis_VI_Agents.pdf
- Myasthenia_Gravis_Agents.pdf
-
N
Back to top -
O
Back to top -
P
- Palynziq.pdf
- Peanut_Allergy.pdf
- Pompe_Disease_Agents.pdf
- Primary_Hemophagocytic_Lymphohistiocytosis_(HLH)_Agents.pdf
- Primary_Hyperoxaluria_Agents.pdf
- Pulmonary_Biologics_for__Asthma_and_Eosinophilic_Conditions.pdf
-
Q
Back to top -
R
- Radicava.pdf
- Reblozyl.pdf
- Respiratory_Agents_Monoclonal_antibodies_Anti-IL_Anti-IgE.pdf
- Rituximab.pdf
- Rytelo.pdf
-
S
- SMN2_Splicing_Modifiers_for_the_Treatment_of_Spinal_Muscular_Atrophy_(SMA).pdf
- Somatostatin_Analogs_and_Growth_Hormone_Receptor_Antagonists.pdf
- Spravato.pdf
- Synagis.pdf
-
T
- Transthyretin-mediated_Amyloidosis_Agents.pdf
- Treatment_of_Hereditary_Angioedema.pdf
- Treatments_for_Plasminogen_Deficiency_Type_1_(PLD1).pdf
- Type_I_Interferon_Receptor_Antagonist.pdf
- Tzield.pdf
-
V
- VEGF_Inhibitors_for_Ophthalmic_Conditions.pdf
- Vasodilators_for_Pulmonary_Hypertension.pdf
- Veopoz.pdf
- Vimizim.pdf
- Vyjuvek.pdf
-
W
Back to top -
X
Back to top -
Z
Back to top